Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience

被引：0
|
作者：
Gowin, Krisstina L. [1 ]
Jain, Tania [1 ]
Kosiorek, Heidi E. [2 ]
Camoriano, John [1 ]
Tibes, Raoul [1 ]
Palmer, Jeanne [1 ]
Mesa, Ruben A. [1 ]
机构：
[1] Mayo Clin Arizona, Hematol Oncol, Scottsdale, AZ USA
[2] Mayo Clin, Scottsdale, AZ USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Alopecia areata during pegylated interferon alpha-2a: A report of two cases
    Ge, L.
    Lowe, P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 51 - 51
  • [42] Pegylated Interferon Alpha-2a and Ribavirin in the Treatment of Children with Chronic Hepatitis C
    Pawlowska, Malgorzata
    Halota, Waldemar
    GASTROENTEROLOGY, 2009, 136 (05) : A839 - A839
  • [43] Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients
    Ucmaky, Hasan
    Koekoglu, Oemer Faruk
    Hosoglu, Salih
    Dogan, Ekrem
    Sayarlioglu, Hayriye
    Kuzhan, Nuretdin
    Isik, Ismet Onder
    RENAL FAILURE, 2008, 30 (02) : 227 - 232
  • [44] USE OF DIRECT ORAL ANTICOAGULANTS IN MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE
    Renso, R.
    Coccini, V.
    Carpenedo, M.
    Carrer, A.
    Rossi, F.
    Gambacorti-Passerini, C.
    Elli, E. M.
    HAEMATOLOGICA, 2019, 104 : 40 - 40
  • [45] PEGYLATED INTERFERON TREATMENT IMPROVES SURVIVAL IN POLYCYTHEMIA VERA PATIENTS: A SINGLE CENTER EXPERIENCE
    Crisa, E.
    Garvey, K.
    Benevolo, G.
    Aguzzi, C.
    Barbara, N.
    Borchiellini, A.
    Beggiato, E.
    Manzini, P.
    di Celle, P. Francia
    Riera, L.
    Vitolo, U.
    Boccadoro, M.
    Ferrero, D.
    HAEMATOLOGICA, 2015, 100 : 532 - 532
  • [46] OUR EXPERIENCE OF THE TREATMENT OF SELECTED DERMATOSES WITH INTERFERON ALPHA-2A
    BOTEV, N
    BEROVA, N
    ANDREEV, V
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 543 - 543
  • [47] Efficacy and tolerability of pegylated interferon alpha-2a plus ribavirin versus pegylated interferon alpha-2b plus ribavirin, in treatment naive chronic hepatitis C patients
    Lee, S. Y.
    Lee, S.
    Ko, K. S.
    Kim, I. H.
    Kim, S. H.
    Kim, S. W.
    Lee, S. O.
    Lee, S. T.
    Kim, D. G.
    Choi, C. S.
    Cho, E. Y.
    Kim, H. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A176 - A176
  • [48] Pegylated interferon 2a and ruxolitinib induce a high rate of oral complications among patients with myeloproliferative neoplasms
    Orliaguet, Marie
    Boisrame, Sylvie
    Eveillard, Jean-Richard
    Pan-Petesch, Brigitte
    Couturier, Marie-Anne
    Rebiere, Vincent
    Guillerm, Gaelle
    Le Bousse-Kerdiles, Marie-Caroline
    Misery, Laurent
    Lippert, Eric
    Ianotto, Jean-Christophe
    EJHAEM, 2020, 1 (01): : 350 - 352
  • [49] Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon
    De Simone, L.
    Gentile, P.
    Aldigeri, R.
    Mastrofilippo, V.
    Bolletta, E.
    Gozzi, F.
    Adani, C.
    Salvarani, C.
    Cimino, L.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (05) : 678 - 682
  • [50] Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms
    Forsyth, Cecily J.
    Chan, Wai-Hoong
    Grigg, Andrew P.
    Cook, Nathalie C.
    Lane, Steven W.
    Burbury, Kate L.
    Perkins, Andrew C.
    Ross, David M.
    INTERNAL MEDICINE JOURNAL, 2019, 49 (08) : 948 - 954
12345